RegeneRx Biopharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of RegeneRx Biopharmaceuticals generated cash of -$940,718, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$940,718.
Cash Flow
| 2013 | -781.59K | 0 | 646K |
|---|---|---|---|
| 2014 | -1.70M | -13.32K | 2.55M |
| 2015 | -525.34K | -1.07K | 8.1K |
| 2016 | -1.06M | 0 | 1.52M |
| 2017 | -663.08K | 0 | 75.29K |
| 2018 | -888.29K | 0 | 943.84K |
| 2019 | -1.13M | 0 | 1.54M |
| 2020 | -1.00M | 0 | 794.91K |
| 2021 | -990.29K | 0 | 1.79M |
| 2022 | -940.71K | 0 | 0 |
RGRX Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.23M | 427.89K | 639.91K | 237.26K | 181.70K | 769.49K | 317.62K | 844.04K | 6.30K | 141.90K |
Operating activities | ||||||||||
Net income | -1.72M | -1.59M | -1.52M | -1.40M | -1.99M | 286.48K | 229.12K | -5.27M | -2.75M | -671.34K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 1.41K | 2.75K | 3.04K | 3.32K | 3.40K | 4.82K | 4.99K |
Stock-based compensation expense | 511.86K | 397.81K | 332.00K | 269.74K | 276.12K | 271.37K | 342.48K | 239 | 163.43K | 73.22K |
| Deferred income tax benefit | 511.86K | 397.81K | 332.00K | 269.74K | 276.12K | 271.37K | 342.48K | 239 | 163.43K | 73.22K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 170 | 24.31K | -4.35K | -48.75K | 25.97K | -9.23K | -65.43K | -91.48K | -344.60K | -59.89K |
Cash generated by operating activities | -940.71K | -990.29K | -1.00M | -1.13M | -888.29K | -663.08K | -1.06M | -525.34K | -1.70M | -781.59K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.07K | -13.32K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.07K | -13.32K | 0 |
Financing activities | ||||||||||
Common Stock Issued | 0 | 1.75M | 241.91K | 240.62K | 943.84K | 75.29K | 1.52M | 8.1K | 2.5M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -234 | -550.80K | 1.3M | 0 | 0 | 0 | 0 | -55 | 0 |
Cash used in financing activities | 0 | 1.79M | 794.91K | 1.54M | 943.84K | 75.29K | 1.52M | 8.1K | 2.55M | 646K |
Net Change In Cash | -940.71K | 803.71K | -212.01K | 402.65K | 55.55K | -587.78K | 451.86K | -526.41K | 837.73K | -135.59K |
Cash at end of period | 290.89K | 1.23M | 427.89K | 639.91K | 237.26K | 181.70K | 769.49K | 317.62K | 844.04K | 6.30K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |